Ebola vaccines help in preventing Ebola virus disease which is a severe, often fatal illness in humans. The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission. Ebola vaccines provide protection by training the immune system to recognize and fight the Ebola virus. The need for Ebola vaccines has been increased recently owing to rising cases of Ebola outbreaks across Africa.
The global Ebola Vaccine Market is estimated to be valued at Us$ 6.72 Bn in 2024 and is expected to exhibit a CAGR Of 9.4% over the forecast period 2024 To 2030.
Key Takeaways
Key players operating in the Ebola Vaccine Market are 10x Genomics, Akoya Bioscience Inc., Biognosys AG, BioSpyder Technologies, Bio-Techne, Bruker, Brooks Automation Inc., Danaher Corporation, Diagenode. Key players are focused on developing improved and more effective Ebola vaccines to help control Ebola outbreaks.
The Ebola vaccine market is witnessing high growth owing to rising cases of Ebola virus diseases globally. As per WHO, as of May 2022, there have been over 32,000 reported cases of Ebola virus disease including over 11,000 deaths since 1976. Repeated Ebola outbreaks in Central African countries are driving the demand for effective Ebola vaccines.
Technological advancements in vaccine development such as reverse genetics technique, virus-like particle (VLP) vaccine platform, DNA vaccines etc are helping researchers develop improved Ebola vaccines with higher immunogenicity and safety profile. This is supporting the growth of the Ebola vaccine market.
Market Trends
Growing R&D investments: Leading vaccine manufacturers and research institutes are increasing their investments in R&D activities focused on developing improved Ebola vaccines. For example, Merck received over $50 million in funding from WHO for development and trials of its VSV-EBOV Ebola vaccine candidate.
Combination vaccines: Researchers are exploring development of novel combination vaccines that can provide protection against Ebola virus disease along with other deadly infections like malaria, cholera, etc. This helps in achieving synergies and offers cost-advantages.
Market Opportunities
Emerging economies: Emerging regions like Africa, Asia Pacific present major growth opportunities for Ebola vaccine market players. These regions have been witnessing rising Ebola cases and have huge populations that remain untapped.
Stockpile initiatives: International organizations like WHO, UNICEF are stockpiling effective Ebola vaccines to help control potential outbreaks rapidly across Central African nations. This presents further demand prospects.
Impact of COVID-19 on Ebola Vaccine Market Growth
The COVID-19 pandemic has significantly impacted the Ebola vaccine market growth. While the demand initially reduced due to supply chain disruptions, it has increased post-pandemic. Ebola outbreaks remained a threat even during the COVID-19 crisis. The pandemic further highlighted the need for effective preventive healthcare measures. This encouraged governments worldwide to focus on vaccine research and production.
The pre-COVID scenario saw steady yet gradual market expansion, with Ebola outbreaks usually localized. Vaccine supply met the relatively low demand. Post COVID-19, governments increased funding to biotech firms for ramping up Ebola vaccine production capacity. International organizations also allocated higher budgets for vaccine procurement and stockpiling. The increased focus on pandemic preparedness accelerated clinical trials and regulatory approvals.
For sustained future growth, focus needs to shift from outbreak response to prevention. Streamlining international collaboration for coordinated vaccine development and distribution is crucial. Establishing regional stockpiles and building local production capacity will enhance access. Continued surveillance of Ebola hotspots and investments in healthcare infrastructure fortification are equally important. Public-private partnerships hold promise for open innovation and affordable solutions.
Geographical Regions with Highest Ebola Vaccine Market Value
Currently, North America accounts for the largest market share in terms value, attributed to sizeable research investments and advanced healthcare systems. However, the market is increasingly shifting to Africa, especially Central and West African countries where Ebola outbreaks frequently occur. The Democratic Republic of Congo alone contributes over 30% of the current global market value due to successive outbreaks since 2018.
The Ebola vaccine market is projected to grow fastest in Latin America through 2030. Countries like Brazil are proactively working to prevent potential outbreaks with massive immunization programs for high-risk groups near their borders with affected regions. Universal healthcare reforms and economic growth are facilitating market expansion in the region. Local production through partnerships with global firms could help Latin America emerge as a key market for Ebola vaccines.
Get more insights on this topic :
https://www.coherentmarketinsights.com/market-insight/ebola-vaccine-market-1365
